• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

狂犬病单克隆抗体研究进展。

Advances in the progress of monoclonal antibodies for rabies.

机构信息

Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, PR China.

Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China.

出版信息

Hum Vaccin Immunother. 2022 Dec 31;18(1):2026713. doi: 10.1080/21645515.2022.2026713. Epub 2022 Feb 16.

DOI:10.1080/21645515.2022.2026713
PMID:35172707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8993100/
Abstract

Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) neutralizing the rabies virus could be better in human rabies post-exposure prophylaxis than equine or human rabies immune globulin in terms of supply, cost, and efficacy. This article reviews anti-rabies mAbs produced by multiple techniques, and the results of clinical trials for anti-rabies mAbs cocktails recognizing non-overlapping epitopes are also discussed.

摘要

狂犬病是一种由狂犬病病毒入侵中枢神经系统引起的高致命性人畜共患病。当怀疑接触狂犬病病毒时,应尽快进行暴露后预防。单克隆抗体(mAbs)中和狂犬病病毒在人类狂犬病暴露后预防方面可能优于马或人狂犬病免疫球蛋白,无论是在供应、成本还是疗效方面。本文综述了多种技术生产的抗狂犬病 mAbs,还讨论了针对非重叠表位的抗狂犬病 mAbs 鸡尾酒的临床试验结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e165/8993100/3238f4406b96/KHVI_A_2026713_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e165/8993100/3238f4406b96/KHVI_A_2026713_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e165/8993100/3238f4406b96/KHVI_A_2026713_F0001_OC.jpg

相似文献

1
Advances in the progress of monoclonal antibodies for rabies.狂犬病单克隆抗体研究进展。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2026713. doi: 10.1080/21645515.2022.2026713. Epub 2022 Feb 16.
2
Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models.新型重组人抗狂犬病单克隆抗体奥木替韦单抗在暴露后预防动物模型中的疗效。
Travel Med Infect Dis. 2022 Mar-Apr;46:102267. doi: 10.1016/j.tmaid.2022.102267. Epub 2022 Jan 25.
3
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.抗狂犬病单克隆抗体:目前在预防和治疗中的应用
Curr Opin Virol. 2022 Apr;53:101204. doi: 10.1016/j.coviro.2022.101204. Epub 2022 Feb 10.
4
A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.一种广谱、高效的抗狂犬病人源单克隆抗体鸡尾酒疗法。
PLoS One. 2021 Sep 1;16(9):e0256779. doi: 10.1371/journal.pone.0256779. eCollection 2021.
5
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.开发一种用于人类暴露后狂犬病预防的鼠源单克隆抗体鸡尾酒疗法。
PLoS Negl Trop Dis. 2009 Nov 3;3(11):e542. doi: 10.1371/journal.pntd.0000542.
6
A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis.一种人源单克隆抗体鸡尾酒可广泛中和北美的狂犬病病毒变异株,有望成为狂犬病暴露后预防的候选药物。
Sci Rep. 2022 Jun 7;12(1):9403. doi: 10.1038/s41598-022-13527-0.
7
Development and evaluation of an anti-rabies virus phosphoprotein-specific monoclonal antibody for detection of rabies neutralizing antibodies using RFFIT.用于使用快速荧光灶抑制试验(RFFIT)检测狂犬病中和抗体的抗狂犬病病毒磷蛋白特异性单克隆抗体的研制与评估
PLoS Negl Trop Dis. 2017 Dec 21;11(12):e0006084. doi: 10.1371/journal.pntd.0006084. eCollection 2017 Dec.
8
SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.SYN023,一种新型人源化单克隆抗体鸡尾酒疗法,用于狂犬病暴露后预防。
PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133. doi: 10.1371/journal.pntd.0006133. eCollection 2017 Dec.
9
Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.澳大利亚蝙蝠狂犬病病毒变异株和其他 1 群狂犬病病毒的人源单克隆抗体的分离与鉴定及其强效中和作用
Viruses. 2021 Mar 1;13(3):391. doi: 10.3390/v13030391.
10
[Development of Recombinant Human Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis].[用于暴露后狂犬病预防的重组人单克隆抗体鸡尾酒的研发]
Bing Du Xue Bao. 2016 Jul;32(4):399-403.

引用本文的文献

1
Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis.抗狂犬病病毒单克隆抗体的研究趋势:文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2508559. doi: 10.1080/21645515.2025.2508559. Epub 2025 May 26.
2
Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.狂犬病糖蛋白的深度突变扫描确定了突变限制和抗体逃逸突变。
Cell Host Microbe. 2025 Jun 11;33(6):988-1003.e10. doi: 10.1016/j.chom.2025.04.018. Epub 2025 May 20.
3
Infection and Prevention of Rabies Viruses.

本文引用的文献

1
Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis.SYN023 的安全性、药代动力学和中和活性,SYN023 是两种新型抗狂犬病单克隆抗体混合物,用于狂犬病暴露后预防。
Clin Pharmacol Drug Dev. 2021 Jul;10(7):807-817. doi: 10.1002/cpdd.917. Epub 2021 Jan 25.
2
Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.SYN023 单药或联合狂犬病疫苗的安全性、药代动力学和药效学:一项在中国健康受试者中进行的开放、平行、单次、Ⅰ 期桥接研究。
Antiviral Res. 2020 Dec;184:104956. doi: 10.1016/j.antiviral.2020.104956. Epub 2020 Oct 19.
3
狂犬病病毒的感染与预防
Microorganisms. 2025 Feb 9;13(2):380. doi: 10.3390/microorganisms13020380.
4
Use of Rabies Monoclonal Antibodies in an Abandoned Newborn.狂犬病单克隆抗体在一名弃婴中的应用。
Indian J Pediatr. 2025 May;92(5):557. doi: 10.1007/s12098-025-05459-0. Epub 2025 Feb 20.
5
Safety Evaluation of the Novel Cocktail of Monoclonal Antibodies for Postexposure Prophylaxis in Category III Animal Exposures.新型单克隆抗体鸡尾酒疗法用于Ⅲ类动物暴露后预防的安全性评估。
J Glob Infect Dis. 2024 Oct 18;16(4):140-144. doi: 10.4103/jgid.jgid_71_24. eCollection 2024 Oct-Dec.
6
Rabies in rural northeast India: A case report emphasising the urgency of the One Health approach.印度东北部农村地区的狂犬病:一例强调“同一健康”方法紧迫性的病例报告。
One Health. 2024 Jul 3;19:100850. doi: 10.1016/j.onehlt.2024.100850. eCollection 2024 Dec.
7
Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.狂犬病糖蛋白的深度突变扫描确定了突变限制和抗体逃逸突变。
bioRxiv. 2024 Dec 17:2024.12.17.628970. doi: 10.1101/2024.12.17.628970.
8
Safety assessment of the world's first novel cocktail of two monoclonal antibodies in WHO category-III animal-bite patients.全球首款两种单克隆抗体新型鸡尾酒疗法用于世界卫生组织III类动物咬伤患者的安全性评估。
J Family Med Prim Care. 2024 Oct;13(10):4493-4498. doi: 10.4103/jfmpc.jfmpc_377_24. Epub 2024 Oct 18.
9
Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.从免疫犬中开发新型犬噬菌体展示衍生的抗狂犬病病毒中和单克隆抗体片段。
Sci Rep. 2024 Oct 3;14(1):22939. doi: 10.1038/s41598-024-73339-2.
10
Assessing the Safety of a Novel Monoclonal Antibody Cocktail for Postexposure Prophylaxis in Category III Animal Exposures.评估一种新型单克隆抗体鸡尾酒疗法用于Ⅲ类动物暴露后预防的安全性。
Int J Appl Basic Med Res. 2024 Jul-Sep;14(3):193-198. doi: 10.4103/ijabmr.ijabmr_281_24. Epub 2024 Aug 24.
A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG).一项评估抗狂犬病单克隆抗体鸡尾酒(TwinrabTM)与狂犬病免疫球蛋白(HRIG)的 3 期、随机、开放标签、非劣效性试验。
Clin Infect Dis. 2021 Nov 2;73(9):e2722-e2728. doi: 10.1093/cid/ciaa779.
4
In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models.抗狂犬病单克隆抗体鸡尾酒疗法SYN023在暴露后预防动物模型中的体内疗效
Trop Med Infect Dis. 2020 Feb 21;5(1):31. doi: 10.3390/tropicalmed5010031.
5
Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein.预融合锁定的广谱中和抗体 RVC20 与狂犬病病毒糖蛋白结合的结构。
Nat Commun. 2020 Jan 30;11(1):596. doi: 10.1038/s41467-020-14398-7.
6
Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.近年来,狂犬病暴露后预防用单克隆抗体的研发取得了进展:对临床开发管道的现状进行综述。
Vaccine. 2019 Oct 3;37 Suppl 1:A132-A139. doi: 10.1016/j.vaccine.2018.11.004. Epub 2018 Nov 29.
7
In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants.人源单克隆抗体鸡尾酒疗法(CL184)对多种北美蝙蝠狂犬病病毒变种的体内疗效
Trop Med Infect Dis. 2017 Sep 20;2(3):48. doi: 10.3390/tropicalmed2030048.
8
[Development of Recombinant Human Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis].[用于暴露后狂犬病预防的重组人单克隆抗体鸡尾酒的研发]
Bing Du Xue Bao. 2016 Jul;32(4):399-403.
9
[Generation of Human ScFv Antibodies for Antigenic Site III of Rabies Virus Glycoprotein from Antibody-phage Libraries by Chain Shuffling].通过链改组从抗体噬菌体文库中生成针对狂犬病病毒糖蛋白抗原位点III的人单链抗体片段(ScFv)抗体
Bing Du Xue Bao. 2016 Jul;32(4):393-8.
10
SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.SYN023,一种新型人源化单克隆抗体鸡尾酒疗法,用于狂犬病暴露后预防。
PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133. doi: 10.1371/journal.pntd.0006133. eCollection 2017 Dec.